Qin Xiaojing, Ning Wenjing, Liu Han, Liu Xue, Luo Wenxin, Xia Ningshao
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen 361102, China.
National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Innovation Platform for Industry-Education Integration in Vaccine Research, the Research Unit of Frontier Technology of Structural Vaccinology of Chinese Academy of Medical Sciences, Xiamen University, Xiamen 361102, China.
Acta Pharm Sin B. 2024 Jun;14(6):2361-2377. doi: 10.1016/j.apsb.2024.03.027. Epub 2024 Mar 24.
T cell-redirecting bispecific antibodies are specifically designed to bind to tumor-associated antigens, thereby engaging with CD3 on the T cell receptor. This linkage between tumor cells and T cells actively triggers T cell activation and initiates targeted killing of the identified tumor cells. These antibodies have emerged as one of the most promising avenues within tumor immunotherapy. However, despite success in treating hematological malignancies, significant advancements in solid tumors have yet to be explored. In this review, we aim to address the critical challenges associated with T cell-redirecting bispecific antibodies and explore novel strategies to overcome these obstacles, with the ultimate goal of expanding the application of this therapy to include solid tumors.
T细胞重定向双特异性抗体经过专门设计，可与肿瘤相关抗原结合，从而与T细胞受体上的CD3相互作用。肿瘤细胞与T细胞之间的这种联系会积极触发T细胞活化，并启动对已识别肿瘤细胞的靶向杀伤。这些抗体已成为肿瘤免疫治疗中最有前景的途径之一。然而，尽管在治疗血液系统恶性肿瘤方面取得了成功，但在实体瘤治疗方面尚未取得重大进展。在本综述中，我们旨在解决与T细胞重定向双特异性抗体相关的关键挑战，并探索克服这些障碍的新策略，最终目标是扩大这种疗法的应用范围，使其包括实体瘤。
